Outlook 2024
Annual Industry Ranking And Forecast
VIEW NOWGenerics Bulletin is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Printed By
As Sandoz continues to fight against antimicrobial resistance, the firm opens a new production facility in Austria, strengthening its position in Europe with a vertically integrated production network for penicillin.
As Biocon Biologics makes multiple moves to position its recently-integrated US biosimilars business for success, the firm’s chief commercial officer for advanced markets, Matt Erick, tells Generics Bulletin that US biosimilar competition is a “marathon” that is “not going to be won in the short term.”
The Global Generics & Biosimilars Awards returns to Milan this October, recognizing the top achievements across the generics, biosimilars and value added medicines industries. Entries are now open and you can also book tickets to attend, both of which are free of charge.
The European off-patent drug organization offered a few suggestions to the European Commission’s unveiled Biotech initiative and its key steps that want to improve the region’s biotech sector.
After reporting losses for the past two years, the Chinese pharma announced the first full year of profitability on the back of continued sales of its commercialized assets.
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
As Sandoz continues to fight against antimicrobial resistance, the firm opens a new production facility in Austria, strengthening its position in Europe with a vertically integrated production network for penicillin.
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.
With a UK general election looming, local generics and biosimilars industry association the BGMA has warned that the country will be “deprioritized as a supply market” without a more focused and supportive policy environment for the off-patent sector.
The European off-patent drug organization offered a few suggestions to the European Commission’s unveiled Biotech initiative and its key steps that want to improve the region’s biotech sector.
As Sandoz continues to fight against antimicrobial resistance, the firm opens a new production facility in Austria, strengthening its position in Europe with a vertically integrated production network for penicillin.
After sending warning letters over more than 100 improper patent listings last year, the FTC has backed Amneal in its attempt to fight ProAir originator Teva over asthma inhalers.
A topsy-turvy legal battle going back some years led to a raft of Tecfidera generics being pulled from the market in December last year. Now, three of the affected companies are a step closer to reentering the market, which is set to remain a Tecfidera monopoly until February 2025.
The European off-patent drug organization offered a few suggestions to the European Commission’s unveiled Biotech initiative and its key steps that want to improve the region’s biotech sector.
As Sandoz continues to fight against antimicrobial resistance, the firm opens a new production facility in Austria, strengthening its position in Europe with a vertically integrated production network for penicillin.
After sending warning letters over more than 100 improper patent listings last year, the FTC has backed Amneal in its attempt to fight ProAir originator Teva over asthma inhalers.
A topsy-turvy legal battle going back some years led to a raft of Tecfidera generics being pulled from the market in December last year. Now, three of the affected companies are a step closer to reentering the market, which is set to remain a Tecfidera monopoly until February 2025.
With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.
Even though the cost of Tivicay is 25 times higher in Trinidad and Tobago compared to other countries in the region, GSK says that its pricing is based on several factors such as country income classification.
With a UK general election looming, local generics and biosimilars industry association the BGMA has warned that the country will be “deprioritized as a supply market” without a more focused and supportive policy environment for the off-patent sector.
Meitheal Pharmaceuticals says it is preparing to launch “up to 20 new products” this year in the US following a recent expansion of its generic injectables portfolio.
Aspire Pharma says that its UK launch of fluticasone propionate 400mcg 1mg/ml nasal drops “further establishes Aspire as a premier specialty generics business,” noting that the product is hitting the market in the wake of GSK pulling out, “leading to a possible short supply for patients.”
A raft of different generics saw their average UK trade price more than double in February 2024, according to the latest figures from market researcher WaveData.
An upbeat Sandoz pointed to growth across all its regions and businesses in 2023, as the firm delivered its first annual results as a standalone company.
Something old, but also something new for generic drugs in the latest FDA’s legislative proposal package.
The European off-patent drug organization offered a few suggestions to the European Commission’s unveiled Biotech initiative and its key steps that want to improve the region’s biotech sector.
After reporting losses for the past two years, the Chinese pharma announced the first full year of profitability on the back of continued sales of its commercialized assets.
With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.
The Chinese firm announced a new deal with Costa Rican company SteinCares that handed over the rights to two unnamed biosimilars in the region for an undisclosed sum.
Belgian company Hyloris Pharmaceuticals has reported a 44% revenue increase in its 2023 results while doubling down on its long-standing ambition to have 30 portfolio assets in the near future.
Celltrion has delivered on its long-awaited US launch of its Zymfentra subcutaneous formulation of infliximab, sold in other territories as Remsima SC.
Viatris offered little in the way of detail as it announced a setback for its Mapi Pharma-partnered proposed once-monthly glatiramer acetate product for relapsing forms of multiple sclerosis. The firm has previously shouted from the rooftops about Mapi’s Phase III clinical study and the potential to establish a new standard of care for glatiramer acetate patients.
Generics Bulletin reviews Viatris’ 2023 financial year, and its prospects ahead of a busy 2024.
The European off-patent drug organization offered a few suggestions to the European Commission’s unveiled Biotech initiative and its key steps that want to improve the region’s biotech sector.
After reporting losses for the past two years, the Chinese pharma announced the first full year of profitability on the back of continued sales of its commercialized assets.
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
As Sandoz continues to fight against antimicrobial resistance, the firm opens a new production facility in Austria, strengthening its position in Europe with a vertically integrated production network for penicillin.
After sending warning letters over more than 100 improper patent listings last year, the FTC has backed Amneal in its attempt to fight ProAir originator Teva over asthma inhalers.
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
A topsy-turvy legal battle going back some years led to a raft of Tecfidera generics being pulled from the market in December last year. Now, three of the affected companies are a step closer to reentering the market, which is set to remain a Tecfidera monopoly until February 2025.
With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.
Even though the cost of Tivicay is 25 times higher in Trinidad and Tobago compared to other countries in the region, GSK says that its pricing is based on several factors such as country income classification.
The Chinese firm announced a new deal with Costa Rican company SteinCares that handed over the rights to two unnamed biosimilars in the region for an undisclosed sum.
The pool of prospective Xolair biosimilars is small, with only Teva and Kashiv BioSciences/Alvotech disclosing Phase III comparison trials for their biosimilar products. Ahead of them in the pack, Celltrion has just taken a giant stride towards the first pan-European marketing approval.
With a UK general election looming, local generics and biosimilars industry association the BGMA has warned that the country will be “deprioritized as a supply market” without a more focused and supportive policy environment for the off-patent sector.
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.